MTX monotherapy users (n = 741) | Multiple-nbDMARD users (n = 995) | |
---|---|---|
Patient factors | ||
Work status | 1.28 (0.79–2.09) | 1.94 (1.27–2.95) |
Private insurance | 1.59 (1.06–2.39) | 0.93 (0.65–1.33) |
Disease duration (per 5 years) | 1.02 (0.92–1.13) | 0.89 (0.83–0.96) |
Provider factors | ||
Geographic region | ||
Northeast (reference) | 1 | 1 |
South | 2.76 (1.42–5.36) | 1.26 (0.75–2.12) |
Midwest | 0.94 (0.50–1.79) | 1.24 (0.72–2.12) |
West | 1.18 (0.52–2.69) | 1.33 (0.61–2.89) |
Time period | ||
December 2008–November 2009 | 1.00 | 1.00 |
December 2009–November 2010 | 0.93 (0.56–1.54) | 0.79 (0.52–1.20) |
December 2010–November 2011 | 1.07 (0.63–1.83) | 0.85 (0.54–1.36) |
December 2011-2/2013 | 0.85 (0.48–1.51) | 0.50 (0.30–0.81) |